10th Congress of the
European Society of Contraception
|
||||||
APRIL |
||||||
|
||||||
Results |
||||||
Legend: | 5=excellent | 4=good | 3=average | 2=below average | 1=poor | |
|
title lecture |
content | presentation |
Congress session 1 | ||
– Mood changes/depression | 4,14 | 3,89 |
– Weight changes | 4,00 | 4,07 |
– Bone Mineral Density (BMD) | 4,35 | 4,42 |
– Breakthrough bleeding | 3,91 | 4,00 |
– How often and why do women discontinue their contraceptive method? Results from a French population-based survey |
4,39 | 4,53 |
– Comparison of patients from high risk population with vs, without thrombotic events while exposed to hormonal contraception |
4,11 | 3,86 |
Congress session 2 | ||
– WHO Global STI epidemiology update |
4,00 | 3,96 |
– Testing for STIs in family planning setting – How to make it simple? |
3,74 | 3,74 |
– Guidelines for HPV DNA testing – To test or not to test? |
3,71 | 3,43 |
– Genital Chlamydial Infection: has the risk for tubal factor infertility and adverse pregnancy outcome been exaggerated? |
3,92 | 3,93 |
– To screen or not to screen…are current guidelines for screening all women for Chlamydia under age 25 being followed in primary care and at family planning clinics? |
3,65 | 3,53 |
– First sex: an opportunity of a lifetime for HIV/AIDS prevention |
3,55 | 3,48 |
Congress session 3 |
||
– IUD/IUS in nulliparous women | 3,63 | 3,66 |
– Management of IUD/IUS in special clinical conditions: emergency contraception, actinomyces, HIV, dysplasia, cancers… |
3,77 | 3,54 |
– Non-contraceptive benefits | 4,24 | 4,48 |
– Long-term use/use beyond recommended time | 3,91 | 3,87 |
– The Swing IUS: innovative design for intrauterine contraception | 4,12 | 4,17 |
– Contraception in the postnatal period | 3,50 | 3,53 |
Congress session 4 | ||
– The WHO family planning cornerstones: a living testimony to the power of partnership |
4,61 | 4,23 |
– Implementation of family planning guidelines in Europe – adoption and adaptation |
4,38 | 4,61 |
– Recommended changes in practice | 4,50 | 4,47 |
Congress session 5 |
||
– The challenge of post-abortion contraception | 4,23 | 4,09 |
– Follow-up after induced abortion: current practice and evidence |
4,47 | 4,23 |
– Access to safe abortion: legal and other obstacles |
3,36 | 3,08 |
– A comparison of two dosages of buccal Misoprostol following Mifepristone for early medical abortion |
3,33 | 3,67 |
– Expanding options for in-the-mouth Misoprostol administration following Mifepristone in medical abortion |
3,57 | 4,00 |
Forum 2 | ||
– Sexual education, sexual health training needs | 4,36 | 4,29 |
Forum 3 | ||
– What is required/minimal criteria/what should be examined before prescribing |
3,88 | 4,06 |
Keynote lecture 1 | ||
– HPV vaccination |
4,21 | 4,13 |
Keynote lecture 2 | ||
– Risk of DVT with new molecules |
4,13 | 4,08 |
Keynote lecture 3 | ||
– New developments in contraception |
4,45 | 4,41 |
Plenary session 1 |
||
– Metabolic benefits | 3,96 | 4,02 |
– Menorrhagia | 3,93 | 3,98 |
– Cycle-related symptoms | 4,25 | 4,35 |
Plenary session 2 | ||
– Passion, love and relationship | 4,48 | 4,54 |
– Hormones and sexual behaviour | 4,22 | 4,19 |
– Sexual problems in the family planning consultation-what to do |
4,21 | 4,11 |